Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)
Status:
Unknown status
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
TNF alpha Inhibitors have been very effective in treating rheumatologic diseases as well as
uveitis. Adalimumab is the first member of a new class of TNF antibody compounds developed to
contain exclusively human sequences. We want to test the efficacy and safety of the TNF alpha
Inhibitor Adalimumab in patients with active uveitis despite standard immunosuppressive
therapy.